Evidence map›Paper›PMID 41801406›Full record

ArticleCancer immunology, immunotherapy : CII2026

Chemoradiotherapy facilitates siglec-10

Wenzhi Kong, Penglin Liu, Jiamin Zhang, Qun Liu, Mengqi Deng, Chunyu Xu, Junqi He, Jinwei Miao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wenzhi Kong *Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, China.
Penglin Liu *Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China.
Jiamin ZhangDepartment of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, China.
Qun LiuDepartment of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, China.
Mengqi DengDepartment of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, China.
Chunyu XuDepartment of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, China.
Junqi HeLaboratory for Clinical Medicine, Capital Medical University, Beijing, 100006, China.
Jinwei MiaoDepartment of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing, 100006, China. jinweimiao@ccmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The post-treatment recurrence after chemoradiotherapy remains a major clinical challenge in cervical cancer, and the underlying mechanisms remain incompletely understood. In this study, single-cell RNA sequencing analysis of human cervical cancer tissues before and after concurrent chemoradiotherapy (CCRT) revealed that cervical cancer tumor cells exhibited enhanced stemness along with upregulated expression of CD24 and MUC16 following CCRT. Meanwhile, tumor-associated macrophages exhibited upregulated expression of Siglec-10 and Siglec-9 after CCRT. Siglec-10

Indexed as

CD24 AntigenChemoradiotherapyLectinsMacrophagesProgrammed Cell Death 1 Ligand 2 ProteinSialic Acid Binding Immunoglobulin-like LectinsUterine Cervical NeoplasmsAntigens, CDCA-125 AntigenFemaleHumansMembrane ProteinsReceptors, Cell SurfaceAntigens, CDCA-125 AntigenCD24 AntigenCD24 protein, humanLectinsMembrane ProteinsMUC16 protein, humanPDCD1LG2 protein, humanProgrammed Cell Death 1 Ligand 2 ProteinReceptors, Cell SurfaceSialic Acid Binding Immunoglobulin-like LectinsSIGLEC10 protein, humanSIGLEC9 protein, humanCD24Cervical cancerChemoradiotherapyMacrophageMUC16

Identifiers

PMID41801406
PMCPMC12972391

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.